KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Capital Leases: 2009-2024

Historic Capital Leases for Regeneron Pharmaceuticals (REGN) over the last 15 years, with Dec 2024 value amounting to $720.0 million.

  • Regeneron Pharmaceuticals' Capital Leases changed negligibly% to $720.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $720.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $720.0 million for FY2024, which is negligibly% changed negligibly from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Capital Leases of $720.0 million as of FY2024, which was down 0.00% from $720.0 million recorded in FY2023.
  • Regeneron Pharmaceuticals' Capital Leases' 5-year high stood at $720.0 million during FY2022, with a 5-year trough of $717.2 million in FY2020.
  • Moreover, its 3-year median value for Capital Leases was $720.0 million (2024), whereas its average is $720.0 million.
  • Data for Regeneron Pharmaceuticals' Capital Leases shows a peak YoY increased of 0.46% (in 2020) over the last 5 years.
  • Regeneron Pharmaceuticals' Capital Leases (Yearly) stood at $717.2 million in 2020, then reached $720.0 million in 2022, then remained steady at $720.0 million in 2023, then remained steady at $720.0 million in 2024.